53 results about "Pathogenicity Factors" patented technology

Methods and compositions useful in the detection and identification of species of Candida are disclosed. These species include Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis, each of which is a causative agent for vaginal candidiasis. The compositions of the invention are combinations of oligonucleotides. These oligonucleotides include pairs of forward and reverse primers for polymerase chain reactions, wherein each primer pair is capable of priming the synthesis of an amplicon specific to one of Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis, but preferably is not capable of priming the synthesis of an amplicon specific to any of the other three species. In preferred embodiments, the forward primers of the primer pairs have identical sequences, while each reverse primer of the primer pairs has a unique sequence relative to all of the other reverse primers; or the reverse primers of the primer pairs have identical sequences, while each forward primer of the primer pairs has a unique sequence relative to all of the other forward primers. These unique primer sequences account for the species specificity of the resultant amplicons. The oligonucleotides also include probes capable of detecting these amplicons, and sequencing primers for determining, in primer extension reactions, the nucleotide sequences contained within the amplicons. In preferred methods of the invention, a biological sample is tested for the presence of at least one isolate of Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis by isolating nucleic acid from the sample, attempting a polymerase chain reaction in a mixture containing this nucleic acid and a plurality of these primer pairs, ascertaining whether any amplicon is produced in the mixture using an oligonucleotide probe, and determining the sequence of any resultant amplicon using the sequencing primers. The detection of an amplicon indicates that the sample contains at least one isolate of Candida albicans, Candida glabrata, Candida parapsilosis, or Candida tropicalis, and the nucleotide sequence data is used to determine which of these four Candida species is present.

The present invention is directed to novel nucleotide sequences to be used for diagnosis, identification of the strain, typing of the strain and giving orientation to its potential degree of virulence, infectivity and/or latency for all infectious diseases more particularly tuberculosis. The present invention also includes method for the identification and selection of polymorphisms associated with the virulence' and /or infectivity in infectious diseases more particularly in tuberculosis by a comparative genomic analysis of the sequences of different clinical isolates/strains of infectious organisms. The regions of polymorphisms, can also act as potential drug targets and vaccine targets.; More particularly, the invention also relates to identifying virulence factors of M. tuberculosis strains and other infectious organisms to be included in a diagnostic DNA chip allowing identification of the strain, typing of the strain and finally giving orientation to its potential degree of virulence. Although the present invention has been illustrated with specific reference to the polymorphic region in the Mycobacterium tuberculosis, the said invention is not to be understood and construed as being limited to Tuberculosis but is applicable to all infectious diseases.

The present invention relates to biologically active peptides and conjugated peptides useful as therapeutic or prophylactic agents against diseases or conditions associated with pathogenic factor B1. In a preferred embodiment of the present invention, biologically active PEG-conjugated peptides are provided. In one aspect of the invention, the pharmaceutically active PEG-conjugated peptides of the invention are useful in the treatment of inflammation or pain.

This is a biochemistry detection liquid of urine calcium comprising 1.5-2w/v percents oxalic acid, 1.5-2w/v percents oxalic acid amine, 3.2- 3.5v/v percents glacial acetic acid and distilled water. This invention offers biochemistry detection liquid and self-checking method of urine calcium for the mass scoutting and checking dynamically. Through the recording curve diagram in accordance with series detecting color result one can self-judge something: 1, warning signal of health and pathogenic factor; 2, forepart detectable rate of calcium metabolism overbalancing; 3, the synchronous tracking monitoring of curative effect during the treating course. The above liquid offers the likelihood of carrying out all this function.

The invention discloses application of mycoplasma bovis secretory protein MbovP274 in preparation of mycoplasma bovis diagnostic reagents, drugs or vaccines, and belongs to the technical field of animal infectious disease prevention and treatment. The mycoplasma bovis secretory protein MbovP274 has an amino acid sequence as shown in SEQ ID NO: 2; gene annotation information shows that the amino acid sequence is a functionally-unknown protein; and experiments show that the MbovP274 protein has antigenicity and can react with mycoplasma bovis positive serum instead of mycoplasma bovis negative serum; the MbovP274 protein is identified as a secretory protein through western blot; it is further verified that the protein can induce bovine macrophages to highly express IL-8 and IFN-gamma, the IL-8 is an important neutrophil activating factor, and the IFN-gamma is a wide immunomodulatory factor. According to the research, the MbovP274 is considered to be an important pathogenic factor of mycoplasma bovis and can activate host immunity, and has important potential in research and development of new drugs and vaccines.

This is a biochemistry detection liquid of urine nitrate comprising 0.35-0.45w/v percents sulfanilic acid, 0.2-0.3mgw/v percents alpha-naphthylamine, 20-40v/v percents glacial acetic acid, 1 -2v/v percents carbinol and distilled water. This invention offers biochemistry detection liquid and self-checking method of urine nitrate for the mass scoutting and checking dynamically. Through the recording curve diagram in accordance with series detecting color result one can self-estimate something: 1, warning signal of health and pathogenic factor; 2, forepart detectable rate of bacterial urine; 3, the synchronous tracking monitoring of curative effect during the treating course. The above liquid offer the likelihood of carrying out all this function.

The invention discloses a food-borne disease pathogenic factor prediction method based on a BP neural network, and the method comprises the following steps: S1, collecting data, collecting and arranging food-borne disease accident cases, building a food-borne disease sample analysis database, and recording the feature items contained in each sample; and S2, determining a training set and a test set, and performing attribute selection and neuron definition. The method has the beneficial effects that the deep BP neural network model is established, the network structure is improved by increasingthe number of hidden layers of the neural network, the network calculation complexity is optimized, the food-borne disease epidemiological pathogenic factor accurate analysis and prediction network model is established, and real-time updating and overlapping are performed through the dynamic migration network with a self-learning function; the execution efficiency and sensitivity of the discrimination model network for food-borne disease pathogenic factor prediction are improved; and missing data is preprocessed, data containing missing items is reconstructed and analyzed, and the data is made to participate in effective network calculation.

The invention relates to a method to inhibit gene expression in bacteria, which is referred to here as Antibacterial Gene Silencing (AGS). In particular embodiments, the method is used to protect plants and animals against pathogenic bacteria by targeting pathogenicity factors and/or essential genes in a sequence-specific manner via small non-coding RNAs. The method can also be used to enhance beneficial effects and/or growth of symbiotic or commensal bacteria. The invention involves the exogenous delivery of small RNA entities onto bacteria, either in the form of RNA extracts or embedded into plant extracellular vesicles (EVs), so as to reduce bacterial growth, survival and/or pathogenicity. The invention also describes a method to identify in a rapid, reliable and cost-effective manner, small RNAs that possess antibacterial activity and that have the potential to be further developed as anti-infective agents. In addition, the latter method is instrumental to rapidly characterize any gene from any bacterial species.

The present invention provides a novel polypeptide or polypeptide derivative which has no risk of infection with a pathogen or propagation of a pathogenic factor and of an undesirable side effect, and which is useful as a carrier of various biologically-active substances or apatite, as well as a process for producing the same. More particularly, the present invention provides a polypeptide comprising a peptide unit having an amino acid sequence represented by the formula: -Pro-X-Gly- (wherein X represents Pro or Hyp) and a peptide unit having an amino acid sequence represented by the formula: -Pro-Hyp(O—Y—Z)-Gly- (wherein Y represents a carbonyl group, a saturated or unsaturated hydrocarbon group with or without a carbonyl group, or a saturated or unsaturated hydrocarbon group with or without a carbonyl group, including an aromatic group, and Z represents a carboxyl group), as well as a process for producing the same.

The invention discloses a pyricularia grisea mitophagy related pathogenic factor, a gene and an application thereof. The gene deletion mutation caused by homologous recombination causes slow growth ofpyricularia grisea, reduction of sporulation quantity, reduction of formation of infected hyphae and great reduction of pathogenicity on susceptible rice varieties. Therefore, the most important purpose of the pathogenic factor is to design and screen a compound capable of destroying the expression and shearing of the gene and the expression of the encoded protein, or design and screen a compoundcapable of modifying an amino acid sequence of the protein by applying the achievements, thereby developing a new antifungal drug. Meanwhile, the gene family where the gene is located does not have ahomologous gene in a plant, so that an antifungal drug developed by taking the gene as a target has relatively small influence on a host plant.

Salmonella enteric serotype Typhimurium is a causative agent for gastroenteritis. It is the leading cause of hospitalization and death caused by a food-borne pathogen in the US. As is the case with many gram- negative pathogens, Salmonella spp. use type III secretion systems (T3SS) to deliver proteins to host cells to induce infections. The T3SS uses a molecular syringe and needle, the type III secretion apparatus (T3SA), as a conduit for the transport of the T3SS proteins from the bacteria to the host. Because proteins associated with the tip of the T3SA are extracellular, they are potential protective subunit vaccine candidates against Salmonella. These pathogens also have a T3SS that is involved with intracellular escape from the vacuole with an associated T3SA. Within this invention, we begin to show proof of concept that these proteins are protective.

The invention discloses a pathogenic factor for negatively regulating ustilaginoidea virens spore production, a gene and an application thereof. An amino acid sequence is shown as SEQ ID No. 1, and the gene sequence is shown as SEQ ID No. 2. The researches find that the fungus pathogenic gene ustilaginoidea virens UvPSR1 derived from ustilaginoidea virens plays an important role in fungus vegetative growth, spore yield, infected hypha formation and pathopoiesis process, and the gene or protein encoded by the gene can be used as a target for designing and screening antifungal drugs.

The invention discloses a method, a culture medium and a system for promoting induced pluripotent stem cells to differentiate into peripheral neuronal cells, and the method comprises the following steps: S1, culturing the induced pluripotent stem cells: treating cell culture vessels with vitronectin; S2, inducing the pluripotent stem cells to differentiate into peripheral neural stem cells, using a cell culture vessel treated by recombinant laminin, and using a non-animal-origin peripheral nerve induction culture medium 01 at the same time; and S3, further differentiating the peripheral neural stem cells into peripheral neuronal cells, and culturing by using the cell culture vessel treated by recombinant laminin and a non-animal-origin peripheral nerve induction culture medium 02. Compared with an existing method, the technology is integrally optimized, high-purity peripheral neuronal cells can be prepared through two culture media, chemical components of the culture media are clear, the technology has obvious advantages in quality control of the culture media and quality control of final products, the whole technology can be free of animal origin, the pollution risk of animal-origin pathogenic factors is avoided, the method is suitable for the cell culture vessel with a large surface area, increases the yield of peripheral neuronal cells in each batch, and is beneficial to industrial production.

The invention discloses an adsorbent capable of being used for removing endotoxin and inflammatory factors in the blood of a sepsis patient and a preparation method of the adsorbent. The adsorbent is prepared on the basis of a carrier which is prepared on the basis of a carrier through surface activation and grafting of ligands such as polyamino amino acid or polypeptide and the like, wherein the carrier is prepared by taking nanometer calcium carbonate-styrene-divinylbenzene as a basic framework, a mixture of methylbenzene, gasoline (or liquid wax), multi-carbon alcohol and the like as a pore-foaming agent and benzoyl peroxide as an initiator. The adsorbent has a developed mesoporous structure and a high specific surface area, the synergistic effect of a nanometer material and active ligands greatly improves the removal efficiency of the adsorbent on pathogenic factors in the blood or the plasma, and animal test results show that the survival rate of a sepsis mouse can be effectively improved. The adsorbent is simple to prepare, has an efficient removal effect on endotoxin, TNF-alpha, IL-1beta, IL-6, IL-8 and other pathogenic factors, and is suitable for removing excessive endotoxin and pathogenic inflammatory factors in the body of a patient through blood or plasma perfusion.

The invention belongs to the technical field of biological materials, and particularly relates to a blood purification adsorbent and a preparation method and application thereof. The blood purification adsorbent comprises an inner core with mesopores and macropores, a first outer modification layer distributed in the mesopores of the inner core, and a second outer modification layer distributed inthe macropores of the inner core, wherein the inner core comprises a porous carbon-based material and a porous titanium-based material, the first outer modification layer comprises polyvinyl alcohol,porous zinc oxide and porous tantalum oxide, the second outer modification layer comprises polyethylene glycol and medical macromolecules containing hydroxyl groups, and the ratio of the number of the hydroxyl groups to the number of carbon atoms in the medical macromolecules is not less than 1: 5. The blood purification adsorbent has good mechanical strength, adsorption performance and biocompatibility, and can adsorb pathogenic factors in blood or plasma.

The invention relates to the technical field of biomedicines, and particularly discloses a targeted treating medicine for cardiac microangiopathy caused by Coxsackie B3 virus infection. The targeted treating medicine is miRNA21antagomir, and the nucleotide sequence is 5'-UCAACAUCAGUCUGAUAAGCUA-3'. The targeted treating medicine is an inhibitor specifically targeting highly-expressed miRNA21 in cardiac microvascular endothelial cells, specifically targets highly-expressed miRNA21 molecules, weakens the gene silencing effect of endogenous miRNA21, and inhibits apoptosis of the vascular endothelial cells to maintain the normal physiological functions of microvessels by increasing the expression quantity of target gene protein and regulating related signaling pathways. The targeted treating medicine can be used for treating the cardiac microangiopathy caused by the Coxsackie B3 virus infection, blocks migration of pathogenic factors to a target organ, alleviates myocardial tissue lesions,and is a novel treating medicine for viral myocarditis intervention.

The invention discloses application of caffeol or a caffeol derivative in preparation of anti-candida albicans drugs or anti-candida albicans daily necessities. Candida albicans is taken as a test object, a compound which is efficient, low in toxicity and not prone to generating drug resistance is screened, and it is found that the caffeol or the caffeol derivative has a good inhibition effect on adhesion, hypha formation, biofilm formation and pathogenicity of the Candida albicans. The bean alcohol has a good inhibition effect on mouse oral cavity infection of a candida albicans strain SC5314, and the compound is non-toxic to human cells; the low-concentration kahweol and the low-concentration cafestol have no inhibition effect on cell growth of the candida albicans, which indicates that the effect of the caffeol or the caffeol derivative on the candida albicans does not depend on killing candida albicans cells, but inhibits the expression of pathogenic factors of the candida albicans, so that the caffeol or the caffeol derivative is not easy to generate drug resistance. The caffeol or the caffeol derivative has a good application prospect in the development of novel antifungal drugs, especially in the development of anti-candida albicans drugs.

The invention relates to the technical field of drug therapy, in particular to an application of alpha-tocopherol in preparation of a drug for treating schistosomiasis. According to alpha-tocopherol gavage for mice, schistosome cercariae in the mice have different degrees of immature development, so that alpha-tocopherol can inhibit schistosome development; morphological and ultrastructural observation shows functions of alpha-tocopherol on schistosome development and reproduction, a result discovers that alpha-tocopherol inhibits development of a reproductive organ of schistosome, and accordingly, eggs laid by schistosome in a host are reduced. Eggs are main pathogenic factors of schistosome, alpha-tocopherol can remarkably inhibit reproductive development and egg laying of schistosome, so that alpha-tocopherol can be used for preparing the drug for treating schistosomiasis, and besides, alpha-tocopherol is simple in structure, does not have toxic and side effects and has wide application value.